If Illumina sat on your watchlist instead of in your portfolio, the past year might feel like a missed shot. Investors who held Illumina over the past year are up 76.2%, including dividends. That outcome arrived alongside headlines about NovaSeq X uptake, clinical sequencing demand, and moves into multiomics. The real puzzle is what, back on 10 November 2025, could have signalled that large-scale clinical consumables adoption might matter more than China and funding worries. Narratives are...
Illumina (NasdaqGS:ILMN) has been chosen to perform whole genome sequencing for Singapore's SG-INSIGHT study under National Precision Medicine Phase III. The SG-INSIGHT project targets around 450,000 people, covering roughly one in ten residents of Singapore. The program expands Illumina's earlier work in Singapore from healthy volunteers into broader clinical applications within the public health system. The SG-INSIGHT sequencing mandate for around 450,000 residents is only one part of...
Illumina stock crashed Friday, despite beating third-quarter expectations, on tariff confusion and a shaky backdrop for AI.
Illumina raises its 2026 guidance as strong clinical sequencing demand and NovaSeq X adoption fuel growth despite research weakness and pricing pressures.
Illumina stock is declining despite raised 2026 guidance amid slowing growth outlook. Read more here.
Detailed price information for Illumina Inc (ILMN-Q) from The Globe and Mail including charting and trades.
Evaluate the expected performance of Illumina (ILMN) for the quarter ended September 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
This is the newest page. Registered accounts read further back.